A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose (SAD/MAD) Study to Evaluate the Safety, Tolerability, PK, and Food Effect of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Healthy Participants.
Latest Information Update: 27 Jul 2023
At a glance
- Drugs Osivelotor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Global Blood Therapeutics; Pfizer
Most Recent Events
- 25 May 2023 Status changed from recruiting to completed.
- 15 Aug 2022 Planned End Date changed from 1 Apr 2022 to 31 Mar 2023.
- 15 Aug 2022 Planned primary completion date changed from 1 Jan 2022 to 30 Nov 2022.